EW
CRL icon

Evoke Wealth’s Charles River Laboratories CRL Stock Holding History

Evoke Wealth’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-18
Closed -$4K – 529
2022
Q3 		$4K Sell
18
-18
-50% -$3.89K ﹤0.01% 913
2022
Q2 		$8K Buy
36
+22
+157% +$5.38K ﹤0.01% 803
2022
Q1 		$4K Buy
+14
New +$4.32K ﹤0.01% 942

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Evoke Wealth's CRL Position: Q4 2022 in Review

Evoke Wealth sold out of Charles River Laboratories (CRL) in Q4 2022, closing a stake of 18 shares — an estimated $4K sold.

Evoke Wealth first reported a position in CRL in Q1 2022 and held it in 3 quarters. The position peaked at $8K in Q2 2022. 627 funds tracked by Wall St. Rank hold CRL as of Q4 2022.

  • Evoke Wealth reported no remaining Charles River Laboratories position as of Q4 2022 after selling out during the quarter.
  • Evoke Wealth sold 18 Charles River Laboratories shares in Q4 2022, an estimated $4K.
  • Evoke Wealth first reported a position in Charles River Laboratories in Q1 2022 and held it in 3 quarters.
  • Evoke Wealth's Charles River Laboratories position peaked at $8K in Q2 2022.
  • 627 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2022.

Based on Evoke Wealth's 13F filing for Q4 2022, filed 10 Feb 2023.